Figure 1. Serogroups of Neisseria meningitidis invasive infection cases in the province of Québec, Canada,
|
|
- Maximilian McCarthy
- 6 years ago
- Views:
Transcription
1
2
3 Context Figure 1. Serogroups of Neisseria meningitidis invasive infection cases in the province of Québec, Canada, In Gilca R, Lefebvre B, Bourgault AM, Deceuninck G, Gilca V, Tsang SWR, et al. Invasive Meningococcal disease in Quebec 8 years after the implementation of a public serogroup C Meningococcal immunization program. 29th annual meeting for paediatric infectious disease (ESPID), the Hague, the Netherlands, 7-11 June, 2011.
4 Context Quebec Immunization Committee has recommended to vaccinate all people aged between 2 months and 20 years old living or studying in the region Figure 3. Incidence rates of IMD-B/ p.-y with 95% confidence intervals according age groups and socio-sanitary region, Quebec In De Wals P, Deceuninck G, Dubé E, Gagnon D, Gilca V, Kiely M, et al. Avis sur la pertinence d'une intervention visant à contrôler une incidence élevée d'infections invasives à méningocoque de sérogroupe B dans l'est du Québec. Québec: Institut national de santé publique du Québec, 2014:107 p.
5 Vaccine Acceptance: one aspect of the evaluation of the campaign Enabling factors Barriers Meningitis = unpredictable and potentially fatal high perceived risk and desire for preventive measure Media attention to IMD cases in the region New vaccine vaccine safety concerns Reactogenecity of the vaccine vaccine safety concerns 2-4 doses required High uptake for most vaccines Bakhache P., Rodrigo C., Davie S., Ahuja A,. Sudovar B,. Crudup T., et al. Health Care Providers' and Parents' Attitudes Toward Administration of New Infant Vaccines - A Multinational Survey. European Journal of Pediatrics 172: (2013). Fisher W., Bettinger J., Gilca V., Sampalis J., Brown V., Yaremko J., et al. Understanding Parental Acceptance of a Novel Meningococcal Serogroup B Vaccine for Infants, Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Milan, Italy, May 28-June 1, 2013.
6 Objective To assess the knowledge, attitudes and intention of parents of eligible children and of adolescents targeted to receive the 4CMenB vaccine over time
7 Methods
8 Descriptive results Announcement of the campaign: April 22 th 2014 Start of the campaign: May 4 th 2014 Response rate: 72% (887 interviews) 703 parents of children between 2 months and 16 years-old 92% reported that their child had received all recommended vaccines (<1% completely non vaccinated) 99% knew that a vaccination campaign was launched in their region. 184 adolescents 66% of adolescents reported having received all recommended vaccines (<1% completely non vaccinated) 90% of adolescents knew that a vaccination campaign was launched in their region More girls than boys were aware of the campaign (98 % vs. 83%, p=0.0001)
9 Intention to vaccinate 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Adolescents main 4.8 reasons to Parents main reason 4.3 to intend not to 1.5 intend not to be vaccinated 3.4 vaccinate their child 4.5 with 4CMenB 2.1 with 4CMenB vaccine vaccine 22.1 Lack of interest, time or information about the vaccine 34.9 General opposition to vaccination Low perceived risk 22.4 Parents and adolescents main reasons to intend / having received the 4CMenB vaccine Protection from meningitis General trust in vaccines 54.5 Parents of children between 2 months to <5 years Parents of children between 5 years to <12 years Parents of children between 12 years to <16 years 50.7 Perception that the benefits of the 4CMenB outweighed the risks Knowing someone who suffered from meningitis Ease of access and free vaccine (adolescent only) Adolescents Intend to receive Vaccinated with 4CMenB vaccine Do not intend to receive Do not know
10 Knowledge, beliefs and attitudes % % Parents' knowledge, attitdes and beliefs regarding IMD and the 4CMenB vaccine Catching Meningitis is dangerous for my child Catching Meningitis is dangerous for me I am worried about my child catching Meningitis I am worried about catching Meningitis. Parents with a high school degree or less = more worried than parents with 59 a college or 45 university degree (78%, 63% and 57%, p<0.0001) Someone who is vaccinate against Meningitis presents very little risk of catching this disease. The vaccine against Meningitis is safe Someone who is vaccinate against Meningitis presents very little risk of catching this disease. The vaccine against Meningitis is safe It is my duty to have my child vaccinated in order not to spread the disease to other people in my community. Adolescents' knowledge, attitdes and beliefs regarding IMD and the 4CMenB vaccine More girls than boys (57%, 29%, p=0.0002) It is my duty to be vaccinated in order not to spread the disease to other people in my community. Somewhat agree Totally agree
11 Multivariate analyses (adolescents) Intention not to be vaccinated Have you heard about a vaccination campaign against Meningitis that is ongoing in your region. (NO) Catching Meningitis is dangerous for me. (Disagree) I am worried about catching Meningitis. (Disagree) Someone who is vaccinated against Meningitis presents very little risk of catching this disease. (Disagree) The vaccine against Meningitis is safe. (Disagree) It is my duty to be vaccinated in order no to spread the disease to other people in my community. (Disagree) 1 Adjusted odds ratio with all items in the model. 2 95% Confidence Intervals. Adjusted OR 1 95% CI 2 P value 18,45 4,79 ; 71,13 <0,0001 1,72 0,35 ; 8,45 0,5045 2,91 0,95 ; 8,92 0,0617 1,20 0,16 ; 8,90 0, ,17 5,13 ;123,46 <0,0001 9,41 2,11 ; 42,09 0,0033
12 Objective To describe health professionals opinions regarding the mass vaccination campaign
13 Methods See poster #103 Formation des infirmières dans le cadre de la campagne de vaccination [ ]
14 Results Participants 11 front-line vaccine providers 3 managers 6 physicians and public health professionals The majority was informed and worried about IMD in Saguenay Lac-St-Jean. Some front-line vaccine providers were not aware of the high prevalence of IMD before the launch of the campaign - All were in favour of the campaign
15 Results - The majority thought that: The 4CMenB was safe and effective That parents would be willing to have their child vaccinated if informed about the campaign There was a great collaboration between the provincial, regional and local levels in organizing the campaign - Most considered that their level of knowledge on the 4CMenB vaccine was sufficient - The majority were at ease to recommend the vaccine AND anti-pyretic for parents of young children after the vaccination
16 Results - Participants have noted barriers to the campaign At their own level Rapid roll-out of the campaign lack of time for preparation Issues with the informed consent form Lack of support for novice nurses At the population level Lack of time to organize communication with the public low awareness (lack of demand) and misinformation ( my child already has received the meningococcal vaccine!) Internet and negative information on the vaccine (fears of adverse events) Difficulties anticipated in reaching young adults (17-20 years of age) 4CMenB and pain
17 Discussion
18 Vaccine uptake (first dose) % months to 5 months 6 months to 11 months 1 year to 4 years 5 years to 11 years 12 years to 16 years 17 years to 20 years *Source: V09 Vaccination File, Quebec Ministry of Health and social Services. Report from Vaccine Uptake tab produced by the Infocentre of Public Health at the Institut national de santé publique du Québec, November 17 th 2014 at 14:09. Data transmitted by Eveline Toth et France Markowski, Bureau de surveillance et de vigie, DGSP, MSSS TOTAL
19 Conclusion After the end of the campaign (March - April 2015) Second questionnaire to parents and adolescents Additional information on the perception of the targeted campaign and the determinants of acceptance of the vaccine (all doses or not) Assess potential impact of adverse events after the first dose on the acceptability of the subsequent doses and of other scheduled vaccines Second interviews with health professionals Additional information on knowledge, attitudes, beliefs and practices regarding the 4CMenB vaccine and the campaign
20 Acknowledgements Quebec Ministry of Health for their financial support for this study Research team Dominique Gagnon, INSPQ Denis Hamel, INSPQ Zhou Zhou, Centre de recherche du CHU de Québec Nicole Boulianne, INSPQ Hélène Gagné, DSP du Saguenay-Lac-St-Jean Sylvie Belley, DPS du Saguenay-Lac-St-Jean Monique Landry, MSSS Thanks to the Bureau de Surveillance et de Vigie of Quebec Ministry of Health for providing data on 4CMenB vaccine uptake
In Canada, invasive meningococcal disease (IMD) is endemic with
original article Parents and adolescents willingness to be vaccinated against serogroup B meningococcal disease during a mass vaccination in Saguenay Lac-St-Jean (Quebec) Eve Dubé PhD 1,2,3, Dominique
More informationHPV year 1 in Quebec Different perspectives, different outcomes. Monique Landry MD Ministry of Health of Quebec June 2009
HPV year 1 in Quebec Different perspectives, different outcomes Monique Landry MD Ministry of Health of Quebec June 2009 Outline The program The preparation The results The hypothesis The evaluation THE
More informationPromoVac update. From PromoVac to EMMIE program
PromoVac update From PromoVac to EMMIE program Pr Arnaud Gagneur Département de Pédiatrie, Centre de Recherche clinique CHUS Université de Sherbrooke, Québec, Canada Plan PromoVac concept Motivational
More informationMeningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program
Meningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program Marc H. Lebel, MD, FRCPC John Yaremko, MD, FRCPC Anne Dionne, MD, FRCPC Anne-Julie Gaudreau,
More informationMotivational interviewing session at birth increases vaccination acceptance and uptake
Motivational interviewing session at birth increases vaccination acceptance and uptake Pr Arnaud Gagneur Département de Pédiatrie, Centre de Recherche clinique CHUS Université de Sherbrooke, Québec, Canada
More informationVaccine Hesitancy, Social Media and the HPV vaccine
Vaccine Hesitancy, Social Media and the HPV vaccine Eve Dubé PhD Institut national de santé publique du Québec Centre de recherche du CHU de Québec- Université Laval @DubeEve Objectives Define vaccine
More informationAppendix B Recommendation for enhanced surveillance of gonococcal infection
Appendix B Recommendation for enhanced surveillance of gonococcal infection Enhanced gonococcal infection surveillance Recommendation for enhanced surveillance of gonorrhoea in the context of the increase
More informationSmoking Cessation Counselling
Smoking Cessation Counselling Results of a 2005 Survey of Quebec NURSES Michèle Tremblay, Daniel Cournoyer, Daniela Jukic, Jennifer O Loughlin,, Université de Montréal INTRODUCTION More than 13,000 men
More informationSmoking Cessation Counselling
Smoking Cessation Counselling Results of a 2005 Survey of Quebec PHARMACISTS Michèle Tremblay, Daniel Cournoyer, Jennifer O Loughlin,, Université de Montréal INTRODUCTION More than 13,000 men and women
More informationSmoking Cessation Counselling
Smoking Cessation Counselling Results of a 2005 Survey of Quebec DENTAL HYGIENISTS Michèle Tremblay, Daniel Cournoyer, Jennifer O Loughlin,, Université de Montréal INTRODUCTION More than 13,000 men and
More informationSmoking Cessation Counselling
Smoking Cessation Counselling Results of a 2005 Survey of Quebec PHYSICIANS Michèle Tremblay, Daniel Cournoyer, Jennifer O Loughlin,, Université de Montréal INTRODUCTION More than 13,000 men and women
More informationSmoking Cessation Counselling
Smoking Cessation Counselling Results of a 2005 Survey of Quebec RESPIRATORY THERAPISTS Michèle Tremblay, Daniel Cournoyer, Jennifer O Loughlin,, Université de Montréal INTRODUCTION More than 13,000 men
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
More informationVACCINE COVERAGE IN CANADIAN CHILDREN
VACCINE COVERAGE IN CANADIAN CHILDREN RESULTS FROM THE 2015 CHILDHOOD NATIONAL IMMUNIZATION COVERAGE SURVEY (cnics) PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH TO PROMOTE AND PROTECT THE
More informationPrevalence of genital HPV infection in a population-based pilot study in women living in Canada.
Prevalence of genital HPV infection in a population-based pilot study in women living in Canada. Forest P., Goggin P., Lavoie F., Sauvageau C., Gilca V., Dubé E., Deceuninck G., Coutlée F. Centre Hospitalier
More informationRecognizing Vaccine Success and Addressing Vaccine Hesitancy
Recognizing Vaccine Success and Addressing Vaccine Hesitancy Rosalyn Singleton, MD Adapted from presentation prepared by Carrie L. Byington, MD HA and Edna Benning Presidential Professor University of
More informationReport to/rapport au : Ottawa Board of Health Conseil de santé d Ottawa. Monday October /le lundi 15 octobre 2012
Report to/rapport au : Ottawa Board of Health Conseil de santé d Ottawa Monday October 15 2012/le lundi 15 octobre 2012 Submitted by/soumis par : Dr./D r Isra Levy, Medical Officer of Health/Médecin chef
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationWe have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci
We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci Pressures for new vaccine introduction. International institutions. Vaccine manufacturers National
More informationSCHOOL-BASED IMMUNIZATION COVERAGE IN NOVA SCOTIA: to
Health and Wellness SCHOOL-BASED IMMUNIZATION COVERAGE IN NOVA SCOTIA: 2008-09 to 2011-12 May 23, 2013 Population Health Assessment and Surveillance Acknowledgements Provincial surveillance of school-based
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationSCHOOL-BASED IMMUNIZATION COVERAGE IN NOVA SCOTIA:
SCHOOL-BASED IMMUNIZATION COVERAGE IN NOVA SCOTIA: 2012-2013 February 18, 2015 Population Health Assessment and Surveillance Acknowledgements Provincial surveillance of school-based immunizations would
More informationHealth technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:
Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical
More informationLessons Learned from HPV Vaccine Study Among Young Adult Women and Men
Lessons Learned from HPV Vaccine Study Among Young Adult Women and Men Natalie Joseph, MD, MPH Assistant Professor of Pediatrics/Adolescent Medicine Boston University Medical Center Racial and ethnic differences
More informationagainst serogroup C meningococcus in the
Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada P. De Wals,12 M. Dionne,3 M. Douville-Fradet,3 N. Boulianne,3 J. Drapeau,4 & G. De Serres3 A mass
More informationGestion du plomb dans l eau potable l approche québécoise de santé publique
Gestion du plomb dans l eau potable l approche québécoise de santé publique Management of lead in drinking water - the public health approach in Québec 16th Canadian National Conference on Drinking Water
More informationOpinion. Vaccination Programmes and Health Systems in the EU. Expert Panel on Effective Ways of Investing in Health
Opinion Vaccination Programmes and Health Systems in the EU Expert Panel on Effective Ways of Investing in Health Brussels, 13 September 2018 Expert Panel on Investing in Health Access to innovative medicines
More informationMeningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region
Meningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region Ricardo Rüttimann Pediatric Infectious Diseases FUNCEI
More informationHIV Pre- Exposure Prophylaxis
HIV Pre- Exposure Prophylaxis KNOWLEDGE AND ATTITUDES IN NORTH QUEENSLAND GENERAL PRACTITIONERS Principle Investigator: William Lane Co-Supervisor 1: Professor Clare Heal Co-Supervisor 2: Dr Jennifer Banks
More informationNHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme
NHS public health functions agreement 2017-18 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS public health functions agreement 2017-18 Service specification
More informationInvasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland
Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland Dr Suzanne Cotter, Health Protection Surveillance Centre (HPSC) Scope presentation Meningococccal disease
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationSee Spot Run Meningococcal update 2017
See Spot Run Meningococcal update 2017 Jim Buttery Infection and Immunity Monash Children s Hospital Monash Health Monash University SAEFVIC How serious a disease is N meningitidis? Meningococcal disease
More informationIntroduction and overview of the program; new vaccine pipeline and prioritization process
Immunization for the Modern Family: Western Canada Immunization Forum 2011 Introduction and overview of the program; new vaccine pipeline and prioritization process Monika Naus, MD, MHSc, FRCPC, FACPM
More informationUnderstanding Non-Vaccination for HPV
Understanding Non-Vaccination for HPV Theresa Rohr-Kirchgraber, MD, FACP, FAMWA Executive Director of IU National Center of Excellence in Women s Health With special thanks to Greg Zimet, PhD http://kristeneve.org/home/
More informationIntention to Accept Pandemic H1N1 Vaccine and the Actual Vaccination Coverage in Nurses at a Chinese Children's Hospital
HK J Paediatr (new series) 2011;16:101-106 Intention to Accept Pandemic H1N1 Vaccine and the Actual Vaccination Coverage in Nurses at a Chinese Children's Hospital SS HU, LL YANG, SH CHEN, XF WANG, YF
More informationTRANSPARENCY COMMITTEE OPINION. 4 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 March 2009 MENCEVAX powder and solvent for solution for injection Meningococcal polysaccharide vaccine for serogroups
More informationWhat do we want to know when we assess willingness to be vaccinated? How many/what proportion of eligible ibl individuals id will be vaccinated if a v
Assessing willingness to be vaccinated Bonita Stanton, MD Wayne State University Children s Hospital of Michigan What do we want to know when we assess willingness to be vaccinated? How many/what proportion
More informationMaking Recommendations on Vaccines: Marrying Science and Best Judgment, a provincial perspective
Making Recommendations on Vaccines: Marrying Science and Best Judgment, a provincial perspective Gaston De Serres, MD, PhD Institut national de santé publique du Québec Laval University Active member of
More informationV A C C I N E H E S I TA N C Y :
V A C C I N E H E S I TA N C Y : T H E R O L E O F C O N V E N I E N C E T H E O R E T I C A L A S P E C T S A N D I S S U E S I N C A N A D A S H A N N O N M A C D O N A L D P H D, RN U N I V E R S I
More informationAuthorization for vaccination
FOR USE BY CLSC INFORMATION RELATING TO VACCINATION Free Vaccination programs File no FIRST dose in grade 4 elementary school CONTRAINDICATION TO VACCINATION (specify) You must fill out the vaccination
More informationImpact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England
Impact and effectiveness of national immunisation programmes David Green, Nurse Consultant, Immunisations Public Health England Session objectives Immunisation planning and implementation The impact and
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on CPS Meningococcal Vaccination These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationExperience in Quebec. 20 organizational issues
Lessons learned by the MSSS following the A (H1N1) pandemic Experience in Quebec 20 organizational issues Dr Michel Savard Medical Consultant, MSSS/ DGSP September 14, 2011 11 Background Organizational
More informationCost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada
Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada Derek Weycker, Ph.D. 1 Mark Atwood, M.S. 1 Thomas E. Delea, M.S.I.A. 1 Anoush Youssoufian, B.A. 1 Dion
More informationStage-Based Educational Interventions for Promoting Early Screening Mammography Use among Korean-American Women
Stage-Based Educational Interventions for Promoting Early Screening Mammography Use among Korean-American Women Jin H. Kim, PhD. RN Associate Professor Chamberlain College of Nursing Funded by NIH/NINR
More informationVACCINE COVERAGE IN CANADIAN CHILDREN
VACCINE COVERAGE IN CANADIAN CHILDREN RESULTS FROM THE 2013 CHILDHOOD NATIONAL IMMUNIZATION COVERAGE SURVEY (CNICS) REVISED EDITION FEBRUARY 2017 PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH
More informationOutsourcing in Clinical Trials 1-2 July 2015
Outsourcing in Clinical Trials 1-2 July 2015 Innovating Dr Chris Bailey Babraham Research Campus Babraham Cambridge CB22 3AT UK +44 (0)1223 496115 Vaccines www.immbio.com 1 Utilising Academia for the Benefit
More informationEDUCATION BULLETIN / INFLUENZA A (H1N1)
EDUCATION BULLETIN / INFLUENZA A (H1N1) TO: School boards, CEGEPs, universities and private teaching institutions DATE: November 17, 2009 SUBJECT: Second wave of the Influenza A (H1N1) pandemic in Québec
More informationSource: Portland State University Population Research Center (
Neisseria meningitidis Surveillance Report 2009 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated: June 2011 Background The Active
More information4.1 Key points. 4.2 Monitoring system for acceptance of vaccination
B. Lehmann, R. Eilers, R. Donken, D. Barug, J. Swillens, C. de Vriend, S. Weerdenburg, M. Pot, H. van Keulen, T. Paulussen, K. Vermey, N. Alberts, E. Marra, H.E. de Melker, L. Mollema 4.1 Key points Both
More informationCHOOSING WISELY CANADA DE-IMPLEMENTING LOW VALUE CARE
CHOOSING WISELY CANADA DE-IMPLEMENTING LOW VALUE CARE JANET E. SQUIRES RN, PhD CENTRE FOR IMPLEMENTATION RESEARCH LAUNCH JANUARY 19 TH, 2018 www.ohri.ca PRESENTATION OUTLINE The problem of low value care
More informationIMMUNIZATIONS IN NOTRE DAME DE LOURDES. By: Diane Bosc. Home for the Summer Program June 12 to July 21, Notre Dame de Lourdes, Manitoba
IMMUNIZATIONS IN NOTRE DAME DE LOURDES By: Diane Bosc Home for the Summer Program June 12 to July 21, 2017 Notre Dame de Lourdes, Manitoba Supervisor: Dr. Holly Hamilton BACKGROUND I had the opportunity
More informationCurrent issues with variability in vaccine uptake and what can be done to improve it
Current issues with variability in vaccine uptake and what can be done to improve it 21 June 2018 Dr Vanessa Saliba Consultant Epidemiologist National Infection Service Content Inequalities - legal and
More informationPresentation to Workshop on Enhancing Communication around Influenza Vaccination Susan Goldstein June 2013
Presentation to Workshop on Enhancing Communication around Influenza Vaccination Susan Goldstein June 2013 Working Group Members Xiaofeng Liang, Chair Chinese Center for Disease Control, China Juhani Eskola
More informationGUILLAIN-BARRÉ SYNDROME
ORIGINAL CONTRIBUTION Risk of Guillain-Barré Syndrome Following H1N1 Influenza Vaccination in Quebec Philippe De Wals, PhD Geneviève Deceuninck, MD Eveline Toth, MSc Nicole Boulianne, MSc Denis Brunet,
More informationReasons for vaccine acceptance: parents and girls perspectives
HPV vaccine acceptability Vaccine acceptability was assessed differently depending on the target group (policymakers, health workers, parents, eligible girls). Key research questions for the policymaker
More informationInvasive Meningococcal Disease in Canada: Identifying Research Priorities by Virtual Round Table
Invasive Meningococcal Disease in Canada: Identifying Research Priorities by Virtual Round Table Simon Dobson, Gordean Bjornson, David Scheifele, Julie Bettinger, Natasha Crowcroft, Philippe De Wals, Raymond
More informationImpact of psychosocial issues on cervical cancer prevention among Chinese women in Hong Kong
Impact of psychosocial issues on cervical cancer prevention among Chinese women in Hong Kong Annie NY CHEUNG MBBS, MD, PhD, FRCPath, FHKAM(Path), FIAC, IFCAP Laurence L T Hou Professorship in Anatomical
More informationGaston De Serres, MD, PhD, INSPQ Vaccine Sciences Symposium Wednesday, April 7, 2010 Hart House, University of Toronto
Is more always better: incorporating the concepts of incremental and marginal trade-offs in vaccine program design Gaston De Serres, MD, PhD, INSPQ Vaccine Sciences Symposium Wednesday, April 7, 2010 Hart
More informationMulticomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease Jeffrey J. Stoddard, MD, FAAP Head, Global Medical Affairs Novartis Vaccines and Diagnostics
More informationOpinions of Quebec parents and vaccinators on the usefulness of chickenpox vaccine
ORIGINAL ARTICLE Opinions of Quebec parents and vaccinators on the usefulness of chickenpox vaccine Nicole Boulianne inf MSc 1, Bernard Duval MD MPH FRCPC 1, Gaston De Serres MD PhD 1, Geneviève Deceuninck
More informationTeen Vaccination Campaign - Reaching Out To Teens
Teen Vaccination Campaign - Reaching Out To Teens Disclosures Jennifer Tinney has a financial relationship with GSK through her spouse EPG Technologies has a financial relationship with Health Net through
More informationSUMMARY. Helping Front-Line Health and Social Services Professionals Detect Elder Abuse. Summary. Highlights
Helping Front-Line Health and Social Services Professionals Detect Elder Abuse SUMMARY May 2014 Summary of a scientific advisory entitled Recherche de cas de maltraitance envers des personnes aînées par
More informationMarc Steben, President Marie-Claude Drouin, Coordinator STBBIs Committee/Unit
Working from a sexual health or harm reduction perspective: Integration of HIV, HCV and other sexually transmitted and bloodborne infections (STBBIs): Evidence and practice Marc Steben, President Marie-Claude
More informationThe routine infant meningococcal B (MenB) vaccine against meningitis and septicaemia
The routine infant meningococcal B (MenB) vaccine against meningitis and septicaemia In the UK and Ireland babies are offered the MenB (meningococcal group B) vaccine, Bexsero, as part of the routine immunisation
More informationCommunicating about HPV vaccination: Lessons learned from physicians and parents
Communicating about HPV vaccination: Lessons learned from physicians and parents Melissa B. Gilkey, PhD Assistant Professor of Population Medicine Harvard Medical School & Harvard Pilgrim Health Care Institute
More informationVACCINATION CONVERSATION GUIDE
VACCINATION CONVERSATION GUIDE A helpful tool for discussing vaccines with your patients 2017 GSK group of companies. All rights reserved. Produced in USA. 817419R0 February 2017 How this guide works:
More informationHPV and the Projected Health Policy. Saman Aziz MD, MHPE, MPH University of Illinois at Chicago
HPV and the Projected Health Policy Saman Aziz MD, MHPE, MPH University of Illinois at Chicago Background Preventive care and health education promote health and disease prevention. HPV is a virus passed
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.7 Hib/MenC vaccination programme NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information
More informationMeningitis January Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.
Meningitis January 2016 Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.16 Outline What is meningitis What causes it What are the signs
More informationVaccine hesitancy in the EU: state of play and impact on vaccination programmes
Vaccine hesitancy in the EU: state of play and impact on vaccination programmes Lucia PASTORE CELENTANO, MD, MSc Head of the Vaccine Preventable Diseases Programme, ECDC Addressing vaccine hesitancy in
More informationVaccine Confidence Current Issues and Controversies including HPV vaccine. Dr Brenda Corcoran National Immunisation Office
Vaccine Confidence Current Issues and Controversies including HPV vaccine Dr Brenda Corcoran National Immunisation Office Vaccination beliefs Factors Confidence do not trust vaccine or provider Complacency
More informationBarriers and drivers of seasonal influenza vaccination coverage in the EU. Elisabeth Nicand
Barriers and drivers of seasonal influenza vaccination coverage in the EU Elisabeth Nicand enicand@mesvaccins.net National Influenza schedule in Europe (www.ecdc/ vaccine scheduler) Influenza vaccination
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationStudy population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years.
Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis Parent du Chatelet I, Gessner B
More informationESCMID Online Lecture Library
What would be the best schedule for prevention of meningococcal disease in all ages? Ray Borrow ray.borrow@phe.gov.uk Public Health England, Manchester, UK MCC vaccine programme - UK In November 1999,
More informationBACTERIAL MENINGITIS IN CHILDREN
Overview Bacterial meningitis in children : rare, severe, mostly preventable What should GPs advise Australian parents in 2018? Peter McIntyre Professorial Fellow, National Centre for Immunisation Research
More informationThank you for offering the opportunity to comment on the proposed amendments to the Pharmacy Act (Proposal #16-HLTC005).
Administration & Office of the Medical Officer of Health Telephone: 519-383-8331 160 Exmouth Street Toll-free: 1-800-667-1839 Point Edward, ON N7T 7Z6 Fax: 519-383-7092 www.lambtonhealth.on.ca Ontario
More informationINFLUENCING FLU VACCINATION BEHAVIOR: Identifying Drivers & Evaluating Campaigns for Future Promotion Planning
INFLUENCING FLU VACCINATION BEHAVIOR: Identifying Drivers & Evaluating Campaigns for Future Promotion Planning Cathy St. Pierre, MS ACHA 2011 Annual Conference June 1, 2011 H1N1 Flu Media Coverage Source:
More informationInvasive meningococcal disease
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Invasive meningococcal disease Key facts In 2015, 3 121 confirmed cases of invasive meningococcal disease were reported by 30 EU/EEA Member States
More informationimmunisation adolescents enfants travailleurs personnes âgées avis protection promotion vaccin évaluation calendrier
oreillons poliomyélite diphtérie hépatite A méningocoque enfants hépatite B acceptabilité adolescents varicelle calendrier immunisation coqueluche zona VPH efficacité avis évaluation rage rotavirus rougeole
More informationDe-Sexualizing the HPV Vaccine How to Counsel Your Families
De-Sexualizing the HPV Vaccine How to Counsel Your Families Laura J. Benjamins, MD, MPH Assistant Professor, Adolescent Medicine The University of Texas Medical School, Houston Objectives Understand current
More informationImproving HPV Vaccination Rates in Michigan: A Call To Action
Improving HPV Vaccination Rates in Michigan: A Call To Action Matthew M. Davis, MD, MAPP Chief Medical Executive, Michigan Department of Community Health Professor of Pediatrics and Internal Medicine,
More informationImproving HPV Vaccine Coverage Why We Must and How We Can Do Better
National Center for Immunization & Respiratory Diseases Improving HPV Vaccine Coverage Why We Must and How We Can Do Better Melinda Wharton, MD, MPH Director, Immunization Services Division Illinois State
More informationHae Won KIM. KIM Reproductive Health (2015) 12:91 DOI /s x
KIM Reproductive Health (2015) 12:91 DOI 10.1186/s12978-015-0076-x RESEARCH Open Access Sex differences in the awareness of emergency contraceptive pills associated with unmarried Korean university students
More informationImmunization Report Public Health September 2013
Immunization Report Public Health September 2013 Daycare, school entry and school program immunization enrollment rates, up to 2012 Table of Contents 1. Introduction... 2 2. Data Source... 2 3. Limitations...
More informationSCIENTIFIC ADVICE. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA.
SCIENTIFIC ADVICE Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA www.ecdc.europa.eu ECDC SCIENTIFIC ADVICE Expert opinion on the introduction of the meningococcal
More informationThere are two supplemental tables presented here. The first, Table A.1, compares the items in the
Appendix There are two supplemental tables presented here. The first, Table A.1, compares the items in the modified Carolina HPV Immunization Attitudes and Beliefs Scale (CHIAS) to those included in the
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationwww. russellresearch.com
0 Introduction and Methodology Study Overview The purpose of this study was to understand familiarity, perceptions, and behavior as it relates to human papillomavirus (HPV), hepatitis B, and hepatitis
More informationUsing knowledge interventions to determine stress and future preventative behaviour regarding cervical cancer and the human papilloma virus
Using knowledge interventions to determine stress and future preventative behaviour regarding cervical cancer and the human papilloma virus Clare Austin (Psychology) Cervical cancer, the human papilloma
More informationFAMILY MEDICINE GROUPS AND VISITS TO THE EMERGENCY DEPARTMENT AMONG DIABETICS IN QUEBEC BETWEEN 2000 AND 2011
FAMILY MEDICINE GROUPS AND VISITS TO THE EMERGENCY DEPARTMENT AMONG DIABETICS IN QUEBEC BETWEEN 2000 AND 2011 Renee Carter, Ph.D. candidate, McGill University Amélie Quesnel-Vallée, Ph.D., McGill University
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationResearch Project Update: AFIX Program Strategies for Improving HPV Vaccination Rates in the Field
71272GPmeeting_13: Power Point Presentation Presented by Melissa Gilkey, PhD, Assistant Professor of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute Research Project
More informationvaccination in Canada Bernard Duval, md, mph, frcpc Institut National de Santé Publique du Québec Québec, Canada Sevilla,
Follow-up of hepatitis B vaccination in Canada Bernard Duval, md, mph, frcpc Institut National de Santé Publique du Québec Québec, Canada Sevilla, 2004-03 03-11 HB in Canada Low endemicity: HBsAg+ : 0.5%
More informationIncreasing the uptake of MMR in London: executive summary of findings from the social marketing project, November 2009
Increasing the uptake of MMR in London: executive summary of findings from the social marketing project, November 2009 1 Introduction & approach The London Social Marketing Unit (LSMU joined in April 2009)
More informationExpanded Eligibility for Human Papillomavirus (HPV) Vaccination for Select Male Populations Q&A Document August 2015
Expanded Eligibility for Human Papillomavirus (HPV) Vaccination for Select Male Populations Q&A Document August 2015 1. Can you tell me more about the expanded eligibility criteria for HPV vaccination?
More informationAdolescent AFIX Study: A PHSSR Approach to Improving the Delivery of HPV Vaccine
Adolescent AFIX Study: A PHSSR Approach to Improving the Delivery of HPV Vaccine Research Team Melissa Gilkey, William Calo, Jennifer MacKinnon, Jennifer Leeman, & Noel Brewer Practice Teams Nicole Freeto,
More information